论文库首页  论文库
 
论文编号:
论文题目: A novel monoclonal antibody against the N terminus of A beta(1-42) reduces plaques and improves cognition in a mouse model of Alzheimer's disease
英文论文题目: A novel monoclonal antibody against the N terminus of A beta(1-42) reduces plaques and improves cognition in a mouse model of Alzheimer's disease
第一作者: Xing, HY; Li, B; Peng, D; Wang, CY; Wang, GY; Li, P; Le, YY; Wang, JM; Ye, G; Chen, JH
英文第一作者: Xing, HY; Li, B; Peng, D; Wang, CY; Wang, GY; Li, P; Le, YY; Wang, JM; Ye, G; Chen, JH
联系作者: Chen, JH (reprint author), Third Mil Med Univ, Dept Pharm, Daping Hosp, Chongqing, Peoples R China.
英文联系作者: Chen, JH (reprint author), Third Mil Med Univ, Dept Pharm, Daping Hosp, Chongqing, Peoples R China.
外单位作者单位:
英文外单位作者单位:
发表年度: 2017
卷: 12
期: 6
页码: e0180076
摘要: Senile plaques consisting of Amyloid-beta (4) peptides, in particular A beta(1-42), are the hallmark of Alzheimer's disease (AD) and have been the primary therapeutic targets. Passive immunotherapy with monoclonal antibodies (mAbs) has shown initial success in mouse models of AD. However, the existing A beta-directed mAbs mostly were tested on animal models or patients with advanced disease. The effects and mechanisms of mAbs on animals or human trial participants in the prodromal phase of AD are not fully clarified. In the current study, a novel mAb (3F5) directed against the 1-11 amino acids of A beta(1-42) was generated by immunizing mice with an emulsion of full length human A beta(1-42). The mAb (3F5) showed the ability to disrupt A beta(1-42) aggregation and prevent A beta-mediated neurotoxicity in vitro. In a mouse model of AD, administration with 3F5 for 3 months in 6 months-old mice demonstrated that the mAb specifically bound with A beta(1-42) to promote the depolymerization of A beta fibrils, facilitated endocytosis of A beta(1-42) by microglia, and attenuated the death and apoptosis of neuronal cells, accompanied by neurite outgrowth. APP/PS1 double-transgenic mice treated with 3F5 mAb showed reduced memory loss, cognitive decline, and decreased levels of amyloid deposits in the brain. A beta(1-42) levels in cerebral tissues were also significantly reduced, whereas serum A beta(1-42) was markedly increased. Interestingly, the concentration of 3F5 in peripheral circulation is much higher than that in the brain. These results indicate that 3F5 is able to cross the blood-brain barrier (BBB) to bind A beta and initiates the phagocytosis of antibody/A beta complexes by microglia in the amyloid depositing mice. 3F5 also promotes 4 efflux from the brain. As a consequence, the antibody reduces plaques in the AD mouse brain, in association with reduction in the pathology of AD.
英文摘要: Senile plaques consisting of Amyloid-beta (4) peptides, in particular A beta(1-42), are the hallmark of Alzheimer's disease (AD) and have been the primary therapeutic targets. Passive immunotherapy with monoclonal antibodies (mAbs) has shown initial success in mouse models of AD. However, the existing A beta-directed mAbs mostly were tested on animal models or patients with advanced disease. The effects and mechanisms of mAbs on animals or human trial participants in the prodromal phase of AD are not fully clarified. In the current study, a novel mAb (3F5) directed against the 1-11 amino acids of A beta(1-42) was generated by immunizing mice with an emulsion of full length human A beta(1-42). The mAb (3F5) showed the ability to disrupt A beta(1-42) aggregation and prevent A beta-mediated neurotoxicity in vitro. In a mouse model of AD, administration with 3F5 for 3 months in 6 months-old mice demonstrated that the mAb specifically bound with A beta(1-42) to promote the depolymerization of A beta fibrils, facilitated endocytosis of A beta(1-42) by microglia, and attenuated the death and apoptosis of neuronal cells, accompanied by neurite outgrowth. APP/PS1 double-transgenic mice treated with 3F5 mAb showed reduced memory loss, cognitive decline, and decreased levels of amyloid deposits in the brain. A beta(1-42) levels in cerebral tissues were also significantly reduced, whereas serum A beta(1-42) was markedly increased. Interestingly, the concentration of 3F5 in peripheral circulation is much higher than that in the brain. These results indicate that 3F5 is able to cross the blood-brain barrier (BBB) to bind A beta and initiates the phagocytosis of antibody/A beta complexes by microglia in the amyloid depositing mice. 3F5 also promotes 4 efflux from the brain. As a consequence, the antibody reduces plaques in the AD mouse brain, in association with reduction in the pathology of AD.
刊物名称: PLOS ONE
英文刊物名称: PLOS ONE
论文全文:
英文论文全文:
全文链接:
其它备注:
英文其它备注:
学科: Multidisciplinary Sciences
英文学科: Multidisciplinary Sciences
影响因子: 2.806
第一作者所在部门:
英文第一作者所在部门:
论文出处:
英文论文出处:
论文类别: Article
英文论文类别: Article
参与作者:
英文参与作者:
 
2014 中国科学院上海生命科学研究院 版权所有